Massey physicians named Richmond’s “Top Docs”
VCU Massey Cancer Center physicians were again recognized in Richmond Magazine’s annual list of “Top Docs.” Featured in the magazine’s April 2017 issue, the list includes 34 doctors from varied specialties who provide oncology-related care to Massey’s patients, including 12 who care for pediatric patients in partnership with the Children’s Hospital of Richmond at VCU. The selections were the result of a survey that asked Richmond-area physicians who they would recommend in a range of specialties.
Charles Chalfant named program leader of Cancer Cell Signaling
Massey researcher Charles Chalfant, Ph.D., has been appointed as the co-leader of the Cancer Cell Signaling (CCS) research program at VCU Massey Cancer Center. He will serve in this capacity alongside Andrew C. Larner, M.D., Ph.D., who has also co-led the program with Sarah Spiegel, Ph.D., since its inception in 2011.
Recipe corner: broccoli salad and stir-fried bok choy
What do these stinky vegetables—bok choy, broccoli, Brussels sprouts, cabbage, cauliflower, collard greens, red cabbage, horseradish, kale, mustard greens, Swiss chard and turnips—have in common? They’re some of the members of the cruciferous vegetable family, and they have been linked to reducing risk for heart disease and cancer.
Combating colorectal cancer: Massey expands its colorectal cancer team, preventative services and treatment options
A variety of factors have contributed to parts of eastern and southern Virginia having some of the highest colorectal cancer death rates in the nation. Massey is working to reverse this trend by expanding it's care team, offering cutting-edge treatment options and working to improve the health of at-risk communities.
Massey pilot study could help identify breast cancer patients who would benefit from preoperative hormone therapy as alternative to chemotherapy
Preliminary findings from a pilot study led by VCU Massey Cancer Center suggest that it may be possible to use genetic testing to identify more breast cancer patients who would benefit from hormone therapy as an alternative to chemotherapy. Hormone therapy, also known as endocrine therapy, lowers estrogen levels or completely restricts estrogen from acting upon breast cancer cells, and its increased use could spare patients from the treatment side effects of chemotherapy and allow for more breast-conserving surgeries.